Johnson & Johnson (J&J) has sued Samsung Bioepis over a ‘concealed plan’ to supply an unnamed health conglomerate with a private label biosimilar version of blockbuster Stelera (ustekinumab).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback